Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
Chiu CH, Lin MC, Wei YF, Chang GC, Su WC, Hsia TC, Su J, Wang AK, Jen MH, Puri T, Shih JY. Chiu CH, et al. Among authors: wei yf. Target Oncol. 2023 Jul;18(4):505-515. doi: 10.1007/s11523-023-00975-5. Epub 2023 Jun 17. Target Oncol. 2023. PMID: 37329423 Free PMC article. Clinical Trial.
Defective formyl peptide receptor 2/3 and annexin A1 expressions associated with M2a polarization of blood immune cells in patients with chronic obstructive pulmonary disease.
Chen YC, Lin MC, Lee CH, Liu SF, Wang CC, Fang WF, Chao TY, Wu CC, Wei YF, Chang HC, Tsen CC, Chen HC; Taiwan Clinical Trial Consortium of Respiratory Disease (TCORE) group. Chen YC, et al. Among authors: wei yf. J Transl Med. 2018 Mar 15;16(1):69. doi: 10.1186/s12967-018-1435-5. J Transl Med. 2018. PMID: 29544524 Free PMC article.
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L. Yang JC, et al. Among authors: wei yf. J Thorac Oncol. 2019 May;14(5):933-939. doi: 10.1016/j.jtho.2019.02.001. Epub 2019 Feb 11. J Thorac Oncol. 2019. PMID: 30763730 Free article. Clinical Trial.
Mortality and vertebral fracture risk associated with long-term oral steroid use in patients with chronic obstructive pulmonary disease: A systemic review and meta-analysis.
Chang YP, Lai CH, Lin CY, Chang YC, Lin MC, Chong IW, Sheu CC, Wei YF, Chu KA, Tsai JR, Lee CH, Chen YC. Chang YP, et al. Among authors: wei yf. Chron Respir Dis. 2019 Jan-Dec;16:1479973119838280. doi: 10.1177/1479973119838280. Chron Respir Dis. 2019. PMID: 30939917 Free PMC article.
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study.
Wei YF, Huang WT, Liu TC, Shieh JM, Chian CF, Wu MF, Chang CC, Lin CH, Ko JC, Lin CM, Hsia TC. Wei YF, et al. J Cancer. 2019 Jul 10;10(17):4151-4158. doi: 10.7150/jca.30507. eCollection 2019. J Cancer. 2019. PMID: 31417660 Free PMC article.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
335 results